| 2026-08-13 | Press release | Press release |
| 2026-08-13 | Press release | Nektar Therapeutics Announces Second Quarter 2026 Financial Results |
| 2026-07-28 | Press release | Press release |
| 2026-07-28 | Press release | Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U. |
| 2026-07-24 | Press release | Press release |
| 2026-07-24 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-21 | Press release | Press release |
| 2026-07-21 | Press release | Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldes |
| 2026-06-26 | Press release | Press release |
| 2026-06-26 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-03 | Press release | Press release |
| 2026-06-03 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-27 | Press release | Press release |
| 2026-05-27 | Press release | Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York |
| 2026-05-07 | Press release | Press release |
| 2026-05-07 | Press release | Nektar Therapeutics Reports First Quarter 2026 Financial Results |
| 2026-05-01 | Press release | Press release |
| 2026-05-01 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-28 | Press release | Press release |
| 2026-04-28 | Press release | Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial |
| 2026-04-23 | Press release | Press release |
| 2026-04-23 | Press release | Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option |
| 2026-04-21 | Press release | Press release |
| 2026-04-21 | Press release | Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering |
| 2026-04-20 | Presentation | Analyst and Investor Event with Alopecia Areata Experts Presentation |
| 2026-04-20 | Press release | Press release |
| 2026-04-20 | Press release | Press release |
| 2026-04-20 | Press release | Nektar Therapeutics Announces Proposed Public Offering |
| 2026-04-20 | Press release | 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Sev |
| 2026-04-19 | Press release | Press release |
| 2026-04-19 | Press release | Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its RE |
| 2026-03-28 | Press release | Press release |
| 2026-03-20 | Press release | Press release |
| 2026-03-20 | Press release | Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Der |
| 2026-03-12 | Press release | Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-06 | Press release | Press release |
| 2026-03-06 | Press release | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-02 | Presentation | TD Cowen 46th Annual Health Care Conference Presentation |
| 2026-02-26 | Press release | Press release |
| 2026-02-26 | Press release | Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close |